Pay in 4 interest-free payments of $5.00 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
In the 2025 SURMOUNT-5 trial, adults with obesity but without diabetes received tirzepatide or semaglutide once weekly for 72 weeks
| Frequently asked questions | Take home message Mounjaro (tirzepatide) produces significantly greater weight loss and blood sugar control than Ozempic (semaglutide) at their highest doses
These compelling data suggest that the endogenous GLP-1 is necessary for curbing the reward experience from drugs
Personalized physician guidance ensures safer outcomes while helping patients achieve realistic and effective results
US$ 22.01
US$ 20.65
US$ 24.13
US$ 26.09
US$ 29.50
